Healthcare News | BioTuesdays by Kilmer Lucas IR

Markets

Dawson James cuts Soligenix to neutral; PT to $2 from $3

Dawson James Securities downgraded Soligenix (NASDAQ:SNGX) to “neutral” from “buy” and reduced its price target to $2 from $3, citing a model update for dilution. The stock closed at $2.13 on July 27. “We have updated...

July 28, 2020

Developments

Celsion randomizes first patients in Phase 1/2 ovarian cancer study

Celsion (NASDAQ:CLSN) randomized the first two patients in the Phase 2 portion of its Phase 1/2 study evaluating GEN-1 for the treatment of advanced ovarian cancer. GEN-1 is an interleukin-12 DNA plasmid vector...

July 27, 2020

Developments

Immunic reports first patients enrolled in Phase 2 COVID-19 trial

The first patients have been enrolled in an investigator-sponsored Phase 2 study evaluating Immunic Therapeutics‘ (NASDAQ:IMUX) IMU-838 for the treatment of COVID-19. IMU-838 is a selective immune modulator that...

July 27, 2020

Markets

Maxim ups Heat Biologics PT to $5 from $2

Maxim Group raised its price target for Heat Biologics (NASDAQ:HTBX) to $5 from $2, citing the potential of the company’s vaccine platform to produce long-lasting cellular immunity against COVID-19. The stock closed at...

July 27, 2020

Markets

SVB Leerink starts Immatics at OP; PT $17

SVB Leerink initiated coverage of Immatics (NASDAQ:IMTX) with an “outperform” rating and $17 price target. The stock closed at $10.57 on July 24. Immatics is developing T-cell receptor (TCR)-based immunotherapies and...

July 27, 2020

Markets

Dawson James starts OncoSec Medical at buy; PT $10

Dawson James Securities launched coverage of OncoSec Medical (NASDAQ:ONCS) with a “buy” rating and $10 price target. The stock closed at $3.19 on July 24. OncoSec has developed a plasmid-based vector that is delivered...

July 27, 2020

Markets

BTIG starts new coverage of Precision BioSciences at buy; PT $16

BTIG analyst Thomas Shrader assumed coverage of Precision BioSciences (NASDAQ:DTIL) with a “buy” rating and $16 price target. The stock closed at $7.41 on July 24. “We like Precision Biosciences in the race to develop...

July 27, 2020

Developments

PolarityTE reports positive topline data from diabetic foot ulcer trial

PolarityTE (NASDAQ:PTE) reported positive topline results from its trial evaluating SkinTE for the treatment of diabetic foot ulcers. SkinTE is a human cellular and tissue-based product derived from a patient’s own skin...

July 24, 2020

Developments

miRagen cobomarsen gets FDA orphan drug designation for T-cell lymphoma

miRagen Therapeutics’ (NASDAQ:MGEN) cobomarsen was granted FDA orphan drug designation for the treatment of T-cell lymphoma. Cobomarsen, an inhibitor of microRNA-155, is being evaluated in a Phase 1 and Phase 2 trial...

July 24, 2020

Markets

HCW ups Aravive PT to $26 from $15

H.C. Wainwright raised its price target for Aravive (NASDAQ:ARAV) to $26 from $15 after the company announced successful completion of its Phase 1b trial testing AVB-500 in patients with platinum resistant ovarian...

July 23, 2020

Markets

BTIG starts 89bio at buy; PT $51

BTIG launched coverage of 89bio (NASDAQ:ETNB) with a “buy” rating and $51 price target. The stock closed at $33.14 on July 22. 89bio is developing BIO89-100, a stabilized fibroblast growth factor 21 (FGF21) analog, for...

July 23, 2020

Executive Moves

Canaccord boosts healthcare investment banking team

Canaccord Genuity named Thomas O’Connor as managing director, co-head of U.S. healthcare investment banking, with long-time partners, Matt Steere and Eugene Rozelman, joining Mr. O’Connor as fellow co-heads of the U.S...

July 23, 2020

Dawson James cuts Soligenix to neutral; PT to $2 from $3

Celsion randomizes first patients in Phase 1/2 ovarian cancer study

Immunic reports first patients enrolled in Phase 2 COVID-19 trial

Maxim ups Heat Biologics PT to $5 from $2

SVB Leerink starts Immatics at OP; PT $17

Dawson James starts OncoSec Medical at buy; PT $10

BTIG starts new coverage of Precision BioSciences at buy; PT $16

PolarityTE reports positive topline data from diabetic foot ulcer trial

miRagen cobomarsen gets FDA orphan drug designation for T-cell lymphoma

HCW ups Aravive PT to $26 from $15

BTIG starts 89bio at buy; PT $51

Canaccord boosts healthcare investment banking team

Follow Us

General

More

Sign up for the BioTuesdays weekly newsletter